Alexander Pym

Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.

Publisher: Oxford University Press (OUP)

Date: 31-01-2016

DOI: 10.1093/JAC/DKV470

Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis

Publisher: American Society for Microbiology

Date: 2016

DOI: 10.1128/AAC.01195-15

Abstract: Rifabutin, used to treat HIV-infected tuberculosis, shows highly variable drug exposure, complicating dosing. Effects of SLCO1B1 polymorphisms on rifabutin pharmacokinetics were investigated in 35 African HIV-infected tuberculosis patients after multiple doses. Nonlinear mixed-effects modeling found that influential covariates for the pharmacokinetics were weight, sex, and a 30% increased bioavailability among heterozygous carriers of SLCO1B1 rs1104581 (previously associated with low rif in concentrations). Larger studies are needed to understand the complex interactions of host genetics in HIV-infected tuberculosis patients. (This study has been registered at ClinicalTrials.gov under registration no. NCT00640887.)

Paradoxical Hypersusceptibility of Drug-resistant M ycobacterium tuberculosis to β-lactam Antibiotics

Publisher: Elsevier BV

Date: 07-2016

DOI: 10.1016/J.EBIOM.2016.05.041

Liverpool School Of Tropical Medicine

Location: United Kingdom of Great Britain and Northern Ireland

View Organisation

Royal College Of Physicians

Location: United Kingdom of Great Britain and Northern Ireland

View Organisation

University College London

Location: United Kingdom of Great Britain and Northern Ireland

View Organisation

University Of Cambridge

Location: United Kingdom of Great Britain and Northern Ireland

View Organisation

KwaZulu-Natal Research Institute For Tuberculosis And HIV

Location: South Africa

View Organisation